Despite significant challenges, Beximco Pharmaceuticals posted a profit of Tk 6.99 billion in FY25, the highest annual earnings since its stock market listing, driven by strong sales growth.
In a significant development, the drug maker approved its overdue quarterly financial statements and the audited annual financial statement for FY25 at a special board meeting on Tuesday.
The drug manufacturer's consolidated earnings per share (EPS) rose about 20 per cent year-on-year to Tk 15.56 in FY25. Its stand-alone profit also surged around 20 per cent year-on-year to Tk 6.71 billion, also the highest annual profit.
Riding on the record earnings, the board of directors declared a 47.5 percent cash dividend for FY25, also the highest cash payout in the company's history.
The company is yet to disclose the detailed financial statements for FY25.
However, its nine-month sales jumped 11 per cent year-on-year to Tk 36.62 billion through March 2025.
Nine-month financial performance
The board of directors published nine-month financial reports on Tuesday. The company's profit in July-March of FY26 jumped 33 per cent year-on-year to Tk 7 billion, surpassing its previous year's annual profit.
Its sales also climbed 13 per cent year-on-year to Tk 41.43 billion during the period.
After the completion of the fiscal year in June 2025, Beximco Pharma failed to publish its annual financial statements within the stipulated time amid a prolonged regulatory and legal impasse, leaving investors without updated financial information for months. It also failed to publish quarterly reports for the same reasons.
The delay had raised concerns among investors, including foreigners, some of whom approached the Bangladesh Securities and Exchange Commission (BSEC) seeking regulatory intervention.
Beximco Pharma was also at risk of being delisted from the London Stock Exchange (LSE) where the company issued Global Depository Receipts (GDRs) on the Alternative Investment Market (AIM).
Subsequently, the market regulator permitted the company to hold a board meeting to approve the pending financial statements and stave off delisting from the LSE.
Market analysts said the approval of the overdue accounts removes uncertainties surrounding the company and is expected to improve investor confidence.
Beximco Pharma has experienced a surge in the demand for its products in recent years, both in domestic and export markets.
The latest financial results reinforce Beximco Pharma's position as one of the country's leading pharmaceutical manufacturers and among the most profitable companies listed on the stock exchanges.
babulfexpress@gmail.com